Íæż½ã½ã

  • By clicking "OK" or continuing to use this site, you agree that we may collect and use your personal data and set cookies to improve your experience and customise advertising. To see how, and to learn how to control cookies, please read our Privacy Policy and Cookie Policy.
OK
Advertisement

We only need a few more clicks to be able to show the most read stories for this topic. Take a look at the latest headlines below and help us out by clicking on what you find interesting!

In the last 2 hours
Nature.com01:44
Medpage Today01:32
Yesterday
PR Newswire (Press Release)15:02 19-Sep-24
Nature.com10:05 19-Sep-24
PR Newswire (Press Release)08:56 19-Sep-24
PR Newswire (Press Release)08:36 19-Sep-24
The Motley Fool05:52 19-Sep-24
In the last 7 days
Daily Record23:54 18-Sep-24
The Motley Fool (Australia)22:52 18-Sep-24
The Motley Fool17:57 18-Sep-24
Edinburgh Live17:01 18-Sep-24
The Mirror15:40 18-Sep-24
Zacks14:36 17-Sep-24
Zacks04:05 17-Sep-24
Futurism21:01 16-Sep-24
Medpage Today01:24 16-Sep-24
MailOnline20:50 14-Sep-24
Worcester News06:29 14-Sep-24
Medpage Today01:35 14-Sep-24
News-Medical.Net21:59 13-Sep-24
News-Medical.Net21:19 13-Sep-24
MailOnline19:01 13-Sep-24
UPI14:28 13-Sep-24
Pharmacy Times12:15 13-Sep-24
Journal of American Medical Associations11:53 13-Sep-24
Invezz11:30 13-Sep-24
HealthDay11:06 13-Sep-24
Newswise (Press Release)10:50 13-Sep-24
The Wrap10:47 13-Sep-24
Yahoo! UK & Ireland10:42 13-Sep-24
The Motley Fool08:54 13-Sep-24
The Diabetes Times06:56 13-Sep-24
pharmaphorum06:46 13-Sep-24
HealthDay06:11 13-Sep-24
Vogue05:24 13-Sep-24
The Motley Fool04:00 13-Sep-24
Medpage Today01:18 13-Sep-24
In the last month
Dibesity21:33 12-Sep-24
News-Medical.Net19:55 12-Sep-24
Medical Xpress18:13 12-Sep-24
Zacks14:31 12-Sep-24
Business Insider13:39 12-Sep-24
Zacks12:08 12-Sep-24
Vogue11:43 12-Sep-24
UPI11:21 12-Sep-24
Zacks11:06 12-Sep-24
Benzinga10:12 12-Sep-24
NewsMax09:43 12-Sep-24
BNN Bloomberg07:20 12-Sep-24
HealthDay05:56 12-Sep-24
Zacks04:30 12-Sep-24
Zacks04:09 12-Sep-24
News-Medical.Net23:24 11-Sep-24
Medical Xpress18:17 11-Sep-24
Medical Xpress18:17 11-Sep-24
Medical Xpress18:17 11-Sep-24
Evening Standard18:07 11-Sep-24
MailOnline18:05 11-Sep-24
Forbes18:03 11-Sep-24
The Nittany Turkey (Weblog)16:03 11-Sep-24
BioWorld15:08 11-Sep-24
Pharmaceutical Technology12:11 11-Sep-24
Pharmaceutical Technology09:49 11-Sep-24
Benzinga09:26 11-Sep-24
Forbes08:20 11-Sep-24
The Motley Fool06:51 11-Sep-24
Science Media Centre18:21 10-Sep-24
MailOnline18:09 10-Sep-24
MailOnline12:03 10-Sep-24
PR Newswire (Press Release)08:39 10-Sep-24
Business Wire (Press Release)08:05 10-Sep-24
Fortune06:59 10-Sep-24
pharmaphorum06:54 10-Sep-24
ParentData05:02 10-Sep-24
New Atlas23:57 9-Sep-24
JD Supra15:38 9-Sep-24
PR Newswire (Press Release)07:40 9-Sep-24
MailOnline10:02 8-Sep-24
The Motley Fool06:48 8-Sep-24
Knowridge Science Report06:31 8-Sep-24
view more headlines
20 Sep 01:44

About our Tirzepatide news

Latest news on Tirzepatide, a drug that is being developed as a potential treatment for obesity and type 2 diabetes. It is a synthetic hormone that is designed to mimic the effects of natural hormones called incretins, which help to lower blood sugar and reduce appetite. Tirzepatide has shown promise in clinical trials, producing significant weight loss in people with obesity or type 2 diabetes. It is administered as a once-weekly injection, and it is believed to work by increasing the production of a hormone called GLP-1, which helps to regulate appetite and insulin production. Tirzepatide is currently in late-stage clinical trials, and it is expected to be considered for regulatory approval in the coming years.


Publication filters

Headline Density

Sorry, no headlines or news topics were found. Please try different keywords.